Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ:CYTK)

60.41 -1.78 (-2.86%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytokinetics, Incorporated - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Analyst Ratings for Cytokinetics ↗
 
Via Benzinga
News headline image
Analyst Expectations for Cytokinetics's Future ↗
 
Via Benzinga
News headline image
Cytokinetics Plans To Discontinue Late-Stage ALS Trial Due To Futility ↗
Cytokinetics Incorporated (NASDAQ: CYTK) announced that the Data Monitoring Committee (DMC) for COURAGE-ALS recently convened to conduct the second planned interim analysis of this Phase 3 clinical... 
Via Benzinga
News headline image
Analyst Ratings for Cytokinetics ↗
 
Via Benzinga
News headline image
Cytokinetics Posts Aficamten Data In Patients With Thickened Heart Muscle ↗
 
Via Benzinga
News headline image
FDA Rejects Cytokinetics' Heart Failure Treatment Candidate ↗
 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2023 ↗
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga
News headline image
Cytokinetics's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Analyst Ratings for Cytokinetics ↗
 
Via Benzinga
News headline image
Analyst Ratings for Cytokinetics ↗
 
Via Benzinga
News headline image
Expert Ratings for Cytokinetics ↗
 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About Cytokinetics ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 17, 2023 ↗
 
Via Benzinga
News headline image
A Patent Cliff Is Coming For Bristol — Can Billions In New Products Fill The Gap? ↗
The company's biggest moneymakers are soon to lose patent protection. 
Via Investor's Business Daily
News headline image
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
News headline image
FDA Adcomm Gives Thumbs Down To Cytokinetics' Heart Failure Candidate ↗
 
Via Benzinga
News headline image
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
News headline image
Tesla To $175? Here Are 10 Other Price Target Changes For Friday ↗
Oppenheimer cut CarMax, Inc. (NYSE: KMX) price target from $100 to $75. . Oppenheimer analyst Brian Nagel maintained an Outperform rating on the stock. CarMax shares fell 1.3% to $56.47 in pre-market... 
Via Benzinga
News headline image
Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said ↗
 
Via Benzinga
News headline image
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Where Cytokinetics Stands With Analysts ↗
Cytokinetics (NASDAQ:CYTK) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022 ↗
 
Via Benzinga
News headline image
Why Cytokinetics Is Soaring After A 'Bruising' FDA Meeting For Its Heart Drug ↗
The FDA's experts voted 3-8 against the Cytokinetics heart-failure drug. 
Via Investor's Business Daily
News headline image
Top Stories Today: Jack Dorsey Not Exactly Impressed With Elon Musk's Twitter; Binance Sees $3B Outflow In 7 Days.. ↗
Benzinga 
Via Benzinga
News headline image
Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share. 
Via Benzinga
News headline image
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗
Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%. 
Via Benzinga
News headline image
Cytokinetics CEO: Why It's OK Not Being An Overnight Success ↗
The company hopes to come out next year with at least one heart-failure drug. 
Via Investor's Business Daily
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306% ↗
Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20... 
Via Benzinga
News headline image
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday ↗
Gainers Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility. 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.